Neuregulin1 as novel therapy for heart failure.

abstract：:The ever-growing resistance of pathogens to antibiotics and crop disease due to pest has triggered severe health concerns in recent years. Consequently, there is a need of powerful and protective materials for the eradication of diseases. Metal/metal oxide nanoparticles (M/MO NPs) are powerful agents due to their ther...

journal_title：Current pharmaceutical design

authors： Chaudhary RG,Bhusari GS,Tiple AD,Rai AR,Somkuvar SR,Potbhare AK,Lambat TL,Ingle PP,Abdala AA

更新日期：2019-01-01 00:00:00

abstract：:Polyunsaturated fatty acids (PUFA) are a family of lipids including some subgroups identified by the position of the last double bond in their structure. PUFA n-3 include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), while PUFA n-6 include linoleic acid (LA) and arachidonic a...

journal_title：Current pharmaceutical design

authors： Zuliani G,Galvani M,Leitersdorf E,Volpato S,Cavalieri M,Fellin R

更新日期：2009-01-01 00:00:00

abstract：:The formation of liposomes, nanoparticle micelles, and related systems by mixtures of drugs and/or surfactants is of major relevance for the design of drug delivery systems. We can design new systems using different compounds. Traditionally these systems are created by trial and error using experimental data. However,...

journal_title：Current pharmaceutical design

authors： Messina PV,Besada-Porto JM,Rial R,González-Díaz H,Ruso JM

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel category of oral antidiabetic drugs that inhibit renal glucose reabsorption and increase renal glucose excretion, thus lowering plasma glucose levels. This unique mechanism of SGLT2i action is insulin independent, thus improving glycemic control ...

journal_title：Current pharmaceutical design

authors： Katsiki N,Mikhailidis DP,Theodorakis MJ

更新日期：2017-01-01 00:00:00

abstract：:Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite hi...

journal_title：Current pharmaceutical design

authors： Ali A,Costanzo P,Hoye A

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

journal_title：Current pharmaceutical design

authors： Iorio A,Guercini F,Ferrante F,Nenci GG

更新日期：2005-01-01 00:00:00

abstract：:Thymulin is a thymic hormone exclusively produced by the epithelial cells of the thymus. After its discovery and initial characterization in the '70s, it was demonstrated that the production and secretion of thymulin are strongly influenced by the neuro-endocrine system. Conversely, a growing body of evidence, to be r...

journal_title：Current pharmaceutical design

authors： Reggiani PC,Schwerdt JI,Console GM,Roggero EA,Dardenne M,Goya RG

更新日期：2014-01-01 00:00:00

abstract：:After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinica...

journal_title：Current pharmaceutical design

authors： Illidge TM,Brock S

更新日期：2000-09-01 00:00:00

abstract：:Transfusion-related acute lung injury (TRALI) is a major cause of morbidity and mortality in transfused hosts and like other causes of acute lung injury, there is no effective pharmacologic treatment. The pathophysiology of TRALI is still being defined, but neutrophils have a major role in the pathogenesis of both hum...

journal_title：Current pharmaceutical design

authors： Caudrillier A,Looney MR

更新日期：2012-01-01 00:00:00

abstract：:The metabolic syndrome (MetS) represents a cluster of medical disorders, such as hyperglycemia, dyslipidemia, hypertension, and abdominal obesity that, when occurring together, increase the risk of developing cardiovascular disease. The role of food and nutrients in the aetiology of chronic diseases has become clearer...

journal_title：Current pharmaceutical design

authors： Grosso G,Mistretta A,Marventano S,Purrello A,Vitaglione P,Calabrese G,Drago F,Galvano F

更新日期：2014-01-01 00:00:00

abstract：:There is an increased use of oral anticoagulants for the prevention of venous and arterial thrombosis. Vitamin-K antagonists have been used for decades as the main oral anticoagulants but they have the draback a complex therapeutic management, slow onset of action and by a different oral intake caused by dietary vitam...

journal_title：Current pharmaceutical design

authors： Lamperti M,Khozenko A,Kumar A

更新日期：2019-01-01 00:00:00

abstract：:Two morphological features may be seen as a main result of the cardiovascular cell damage caused by cigarette smoking: myocardial cell necrosis and smoke cardiomyopathy that, however, can lead to cell necrosis in case of chronic prolonged exposure to tobacco smoke. Both these pathological patterns recognise hypoxia as...

journal_title：Current pharmaceutical design

authors： Leone A,Landini L Jr,Biadi O,Balbarini A

更新日期：2008-01-01 00:00:00

abstract：:The prevalence of type 2 diabetes is rising at an alarming rate worldwide. Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the diabetic population. Future CAD risk should be routinely assessed in patients with diabetes as specific subgroups might benefit from information derived from c...

journal_title：Current pharmaceutical design

authors： Karastergiou K,Kaski JC

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Absorption windows in particular segments of the small intestine can contribute to the development of orally administered drug formulations and can limit the bioavailability of released compounds. OBJECTIVE:The aim of this study was to evaluate use of wireless capsule enteroscopy regarding the disintegratio...

journal_title：Current pharmaceutical design

authors： Kvetina J,Tacheci I,Nobilis M,Kopacova M,Kunes M,Bures J

更新日期：2017-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is marked by cognitive dysfunctions and existence of neuropathological hallmarks such as amyloid plaques, and neurofibrillary tangles. It has been observed that a persistent immune response in the brain has appeared as another neuropathological hall...

journal_title：Current pharmaceutical design

authors： Uddin MS,Kabir MT,Al Mamun A,Behl T,Mansouri RA,Aloqbi AA,Perveen A,Hafeez A,Ashraf GM

更新日期：2020-05-31 00:00:00

abstract：:Since the discovery of human immunodeficiency virus (HIV) as a causative agent of acquired immune deficiency syndrome (AIDS) various strategies were employed to counter its devastating actions. One such concept relies on the prevention of HIV entry into host's "competent" cells by means of compounds known as entry inh...

journal_title：Current pharmaceutical design

authors： Micewicz ED,Ruchala P

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Cancer is the world's second-largest cause of death, with an estimated 9.6 million fatalities in 2018. Malignant tumour (cancer) is caused by a mixture of genetic modifications due to the environmental variables that tend to activate or inactivate different genes, ultimately resulting in neoplastic transform...

journal_title：Current pharmaceutical design

authors： Jindal M,Nagpal M,Singh M,Aggarwal G,Dhingra GA

更新日期：2020-01-01 00:00:00

abstract：:Proper understanding of blood-brain barrier (BBB) regulation is crucial to reduce/prevent its disruption during injury. Since high brain complexity makes interpretation of in vivo data challenging BBB studies are frequently performed using simplified in vitro models. Although such models represent an important and fre...

journal_title：Current pharmaceutical design

authors： Ogunshola OO

更新日期：2011-01-01 00:00:00

abstract：:Superparamagnetic iron oxide nanoparticles (SPIONs) comprise a fundamental technology class within the emerging field of nanomedicine, and have been extensively researched for cancer imaging and therapy. This review article will discuss the chemistry and design considerations associated with the synthesis of SPIONs an...

journal_title：Current pharmaceutical design

authors： Yoffe S,Leshuk T,Everett P,Gu F

更新日期：2013-01-01 00:00:00

abstract：:Aspirin is the cornerstone of treatment in patients with coronary artery disease. However, several studies investigating the in vitro response of platelets to the administration of aspirin showed this response to be variable, with some patients exhibiting non-responsiveness or resistance. Aspirin resistance may be cat...

journal_title：Current pharmaceutical design

authors： Papathanasiou A,Goudevenos J,Tselepis AD

更新日期：2009-01-01 00:00:00

abstract：:The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically val...

journal_title：Current pharmaceutical design

authors： Bosco MC,Raggi F,Varesio L

更新日期：2016-01-01 00:00:00

abstract：:Many plant species and tissues have been investigated as production and delivery vehicles for recombinant pharmaceutical proteins. Examples include cultured cells, whole aquatic plants and transgenic plants expressing recombinant proteins in their leaves, seeds, fruits or tubers/roots. Each platform has unique propert...

journal_title：Current pharmaceutical design

authors： Hofbauer A,Stoger E

更新日期：2013-01-01 00:00:00

abstract：:Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the ther...

journal_title：Current pharmaceutical design

authors： Lim KH,Baek KH

更新日期：2013-01-01 00:00:00

abstract：:In this review we discuss the role of protonation states in receptor-ligand interactions, providing experimental evidences and computational predictions that complex formation may involve titratable groups with unusual pKa's and that protonation states frequently change from unbound to bound states. These protonation ...

journal_title：Current pharmaceutical design

authors： Petukh M,Stefl S,Alexov E

更新日期：2013-01-01 00:00:00

abstract：:The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine protease...

journal_title：Current pharmaceutical design

authors： Debowski D

更新日期：2013-01-01 00:00:00

abstract：:Ablation has become an important treatment for many pediatric patients with common supraventricular tachycardias (SVTs). Many multicenter studies have documented that radiofrequency (RF) catheter ablation is a safe and effective procedure for treatment of a large variety of SVTs in children and adults with a high succ...

journal_title：Current pharmaceutical design

authors： De Santis A,Fazio G,Silvetti MS,Drago F

更新日期：2008-01-01 00:00:00

abstract：:Apoptosis is a regulated process leading to cell death, which is implicated both in normal development and in various pathologies including heart failure, stroke and neurodegenerative diseases. Caspase-3, a key enzyme of the apoptotic pathway, is considered as a major target for the treatment of abnormal cell death. M...

journal_title：Current pharmaceutical design

authors： Seaborn T,Masmoudi-Kouli O,Fournier A,Vaudry H,Vaudry D

更新日期：2011-01-01 00:00:00

abstract：:The organ shortage for kidney transplantation remains a challenging issue worldwide. Incompatibility between donor-recipient pairs, commonly occurring among transplant candidates who were sensitized from prior antigen exposure, serves as a significant barrier to kidney transplantation. In efforts to overcome this obst...

journal_title：Current pharmaceutical design

authors： Mustian MN,Locke JE

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Type 2 diabetes mellitus (DM) is associated with a considerable risk of cardiovascular and renal disease, including heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated unprecedented cardiorenal protective effects in large scale clinical trials of patients with or without diabet...

journal_title：Current pharmaceutical design

authors： Karangelis D,Mazer CD,Stakos D,Tzifa A,Loggos S,Verma S,Mitropoulos F

更新日期：2020-11-03 00:00:00

abstract：:Immune complexes are major pathogenic factors contributing to tissue injury in a number of autoimmune diseases. Immune complexes consist of autoantibodies to self-antigens, which initiate an inflammatory response through binding to immunoglobulin Fc receptors (FcRs) or via complement components. The significance of Fc...

journal_title：Current pharmaceutical design

authors： Kleinau S

更新日期：2003-01-01 00:00:00